Radiotherapy Plus Anti-programmed Death Gene-1 (PD-1) and Apatinib for Unresectable Hepato-bilio-pancreatic Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Apatinib
- Hepato-Biliary Neoplasm
- Pancreatic Cancer
- PD-1
- Radiotherapy
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
We will prospectively collect 150 patients who receive radiotherapy+anti-PD-1+apatinib or gemcitabine and cisplatin. Data will be stored in a private database. The process of data collection will be supervised and regular data examination will be performed.
We will prospectively collect 150 patients who receive radiotherapy+anti-PD-1+apatinib or gemcitabine and cisplatin. Data will be stored in a private database. The process of data collection will be supervised and regular data examination will be performed.
Tracking Information
- NCT #
- NCT04365049
- Collaborators
- Not Provided
- Investigators
- Study Chair: Ming Kuang, PhD First Affiliated Hospital, Sun Yat-Sen University
Get Well Soon